期刊： MELANOMA RESEARCH, 2022; 32 (5)
Although there is evidence that chemotherapy can have side effects on metabolism and brain function, there are few studies on the occurrence of these ......
期刊： MELANOMA RESEARCH, 2022; 32 (5)
Despite the dramatic improvement in both overall survival (OS) and progression-free survival (PFS) in patients with metastatic melanoma treated with i......
期刊： MELANOMA RESEARCH, 2022; 32 (5)
Cutaneous melanoma represents a major cause of cancer death in Europe. Without adequate therapy, the 5-year survival rate is 15-20% in distant metasta......
期刊： MELANOMA RESEARCH, 2022; 32 (4)
The effect of serine/threonine-protein kinase B-Raf/mitogen-activated protein kinase (BRAF/MEK) inhibitors on the immune system is not clearly describ......
期刊： MELANOMA RESEARCH, 2022; 32 (5)
Checkpoint immunotherapies (CPIs) have improved outcomes for metastatic melanoma patients, with objective response rates to combination ipilimumab and......
期刊： MELANOMA RESEARCH, 2022; 32 (5)
Melanoma is one of the most aggressive tumors, and in the setting of rising incidence and mortality, there is an urgent need to identify new prognosti......
期刊： MELANOMA RESEARCH, 2022; 32 (5)
Cutaneous melanoma is an aggressive neoplasm with growing incidence and continuous research is undertaken for novel prognostic factors. This current r......
期刊： MELANOMA RESEARCH, 2022; 32 (6)
The widespread use of more sensitive detection tools, such as next-generation sequencing, has increased the identification of a variety of BRAF mutati......
期刊： MELANOMA RESEARCH, 2022; 32 (5)
This study aimed to assess the current management of melanoma from relative to present guidelines and determine changes 5 years ago. An eight-question......
期刊： MELANOMA RESEARCH, 2022; 32 (2)
The purpose of this study is to review the efficacy of radiotherapy combined with immune checkpoint inhibitors (ICIs) in the treatment of melanoma and......
期刊： MELANOMA RESEARCH, 2022; 32 (6)
Nearly half of advanced melanoma patients do not achieve a clinical response with anti-programmed cell death 1 protein (PD1) therapy (i.e. primary res......
期刊： MELANOMA RESEARCH, 2022; 32 (2)
Both BRAF/MEK targeted agents and immunotherapy are approved for the treatment of advanced melanoma. BRAF testing is recommended at the time of advanc......
期刊： MELANOMA RESEARCH, 2022; 32 (6)
Adrenal nonadenomatous tumors (NAT) first identified during pregnancy are very rare and pose a diagnostic and therapeutic dilemma with significant ris......
